Clinical Updates for HM43239 and Luxeptinib
The poster presentation for HM43239 is scheduled for June 10 at
EHA2022 Hybrid Congress
SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing kinase inhibitors to treat hematological malignancies, today announced that the company’s management team, along with guest opinion leaders (KOLs), will provide an update to the investment community on Thursday 2 Junen/a at 4:30 p.m. The event will include an up-to-date review of available clinical data for Aptose’s two investigational products in development for hematological malignancies: HM43239, an oral myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral lymphoid and myeloid kinome inhibitor, in a phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies, and in a separate phase 1 a/b trial in patients with relapsed or refractory AML or at risk of myelodysplastic syndrome (MDS).
Aptose Corporate Update Details
Date and hour : Thursday, June 2, 4:30 p.m. ET
Link to participant webcast: here
The slides will be available on the Aptose website here and a recording of the presentation will be archived shortly after the event ends.
Separately, preclinical data for HM43239 will also be presented in a poster at the EHA2022 Hybrid Congress, to be held in Vienna, Austria, June 9-17, 2022 and virtually. The accepted abstract is published today, Thursday May 12and at 4:00 p.m. CEST / 10:00 a.m. ET.
|Poster presentation details|
|Title:||Myeloid kinome inhibitor HM43239 overcomes acquired resistance in models of acute myeloid leukemia|
|Session title:||Poster session|
|Session Date/Time:||Friday, June 10, 2022, 4:30 p.m. – 5:45 p.m. CEST|
|Final abstract code:||P461|
|The poster will also be available on the presentations page of Aptose’s website here.|
Aptose Biosciences is a clinical-stage biotechnology company engaged in the development of personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s pipeline of small molecule cancer therapeutics includes products designed to provide single-agent efficacy and to enhance the efficacy of other cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products in development for hematological malignancies: HM43239, an oral myeloid kinome inhibitor in an international phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, lymphoid and myeloid kinome inhibitor, in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard treatments, and in a trial of separate Phase 1 a/b in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS). For more information, visit www.aptose.com.
|For more information, please contact:|
|Aptose Biosciences Inc.||LifeSci Advisors, LLC|
|Susan Pietropaolo||Dan Ferry, General Manager|
|Corporate Communication and Investor Relations||617-535-7746|